All Comments by Takaomi Saido

  1. Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1.
  2. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
  3. Amyloid-β associated volume loss occurs only in the presence of phospho-tau.
  4. Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration.
  5. Adaptive responses to alloxan-induced mild oxidative stress ameliorate certain tauopathy phenotypes.
  6. Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms.
  7. Resolving Controversies on the Path to AD Therapeutics
  8. Resolving controversies on the path to Alzheimer's therapeutics.
  9. Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation.
  10. Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence.
  11. Opposing synaptic regulation of amyloid-β metabolism by NMDA receptors in vivo.
  12. Presymptomatic apolipoprotein E genotyping for Alzheimer's disease risk assessment and prevention.
  13. Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers.
  14. Power and pitfalls of the genome-wide association study approach to identify genes for Alzheimer's disease.
  15. Factors responsible for neurofibrillary tangles and neuronal cell losses in tauopathy.